News
Hosted on MSN5mon
Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumoursPalleon Pharmaceuticals has reported the outcomes ... enzyme therapeutic E-602 is based on the company’s oncology platform, Enzyme Antibody Glyco-Ligand Editing (EAGLE). The Glycan-Mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback